Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 14
- Registration Number
- NCT00258427
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Registration Number
- NCT00253487
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 4
- Registration Number
- NCT00253552
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
- Conditions
- Interventions
- Biological: therapeutic allogeneic lymphocytesDrug: busulfanDrug: cyclosporineDrug: fludarabine phosphateDrug: mycophenolate mofetilProcedure: peripheral blood stem cell transplantationRadiation: Total Body Irradiation (TBI)Drug: Granulocyte colony-stimulating factor (G-CSF)Drug: PhenytoinDrug: Methotrexate
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 147
- Registration Number
- NCT00245037
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2018-08-23
- Target Recruit Count
- 7
- Registration Number
- NCT00245115
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00238433
- Locations
- 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2017-11-06
- Target Recruit Count
- 59
- Registration Number
- NCT00238368
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Stem Cell Transplant for Hematological Malignancy
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 330
- Registration Number
- NCT00176930
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplantation for Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 11
- Registration Number
- NCT00176839
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stem Cell Transplant for Bone Marrow Failure Syndromes
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 10
- Registration Number
- NCT00176878
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.